Measurement of Soluble Factors and Particulate Matter in Induced Sputum and EBC in Inflammatory Diseases of the Lung

In the present study inflammatory mediators will be isolated in induced sputum and exhaled breath condensate and will be correlated with particulate matter measured in these samples.Particulate matter will be assessed by partcle size distribution method and shape analysis.

The aim of the study is to perform biological monitoring in environmental and occupational diseases in a non invassive fashion.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Asthma Bronchial Diseases Chronic Disease Chronic Obstructive Pulmonary Disease Disease Attributes Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Interstitial Lung Diseases Lung Diseases Lung Diseases, Interstitial Lung Diseases, Obstructive Occupational Lung Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Hypersensitivity Respiratory Tract Diseases

Age range

7 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Tel-Aviv Sourasky Medical Center

Tel Aviv, 64239, Israel

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Ages 7-80

Exclusion criteria

FEV1 < 75% predicted pO2 < 75

Treatment and study plan

no generic names

Other

Sponsors and collaborators

Lead sponsor

Tel-Aviv Sourasky Medical Center

Other Gov

Registry information

Important dates

First posted: Aug 3, 2007
Registry last updated: Aug 3, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed